undamentalytics Newsletter
Sign in

Aytu Biopharma, Inc income statement

In fiscal 2026, Aytu Biopharma, Inc reported revenue of $57.6m, down 13.3% on the year before, operating income of −$8.3m (a -14.4% margin) and net income of −$14.3m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue003347286697107656658
Cost of revenue—011228364441162121
Gross profit—0222519295267494637
Research and development43610126134310
Selling, general and administrative—4917181935——————
Selling and marketing———————303941222123
General and administrative2——————263129201719
Operating income−6−8−22−20−20−17−21−59−110−17−2−8−8
Interest expense—053113—15542
Net interest income−0−0———————————
Income before tax−6−8−28———−14−58−109−17−10−14−14
Income tax−1−0000000−00200
Net income−6−8−28−23−10−27−14−58−109−17−16−14−14
Diluted EPS−$1920.00−$2014.00−$3237.00−$483.00−$153.10−$34.80−$30.10−$34.80−$37.01−$2.56———
Diluted shares (average)——9m—67m——2m3m7m11m13m12m
EBITDA−6−8−21−16−17−14−15−50−100−87−2−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AQST vs AYTUAYTU vs DERMAYTU vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aytu Biopharma, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aytu Biopharma, Inc.